Tech Company Financing Transactions
Regado Biosciences Funding Round
Regado Biosciences, based in San Francisco, raised $20 million from Domain Associates, Aurora Funds and Quaker Partners.
Transaction Overview
Company Name
Announced On
8/12/2005
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series B
Investors
Domain Associates (Lead Investor) (Jesse Treu)
Aurora Funds (Jeffrey Clark)
Quaker Partners (Sherrill Neff)
Proceeds Purpose
This financing provides further validation of the Regado technology and will allow us to build on the progress generated to date.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
701 Gateway Blvd. 300
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Regado (NASDAQ: RGDO) is a spin-out of the Department of Surgery at Duke University Medical Center. Regado's technology enables the rational design of drug-antidote pairs against any target accessible to the bloodstream.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Laurent Fischer
Chief Financial Officer
Christopher Peetz
Chief Medical Officer
Eric Lefebvre
Chief Operating Officer
Helen Jenkins
Browse more venture capital transactions:
Prev: 8/12/2005: Alphion venture capital transaction
Next: 8/12/2005: Guardium venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs